Regulations.gov document
Reference 14 CCP guidance - Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody…
Supporting & Related Material · FDA-2024-D-2442 · posted Jul 25, 2024
Key facts
| Document ID | FDA-2024-D-2442-0016 |
|---|---|
| Title | Reference 14 CCP guidance - Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2024-D-2442 |
| Posted | Jul 25, 2024 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: